Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Biotech firms join for drug linker
by Ann M. Thayer
April 25, 2016
| A version of this story appeared in
Volume 94, Issue 17
ProBioGen has licensed Eucodis Bioscience’s technology to enzymatically link drugs to antibodies. The German contract manufacturer will offer the technology along with its antibody development services. Eucodis engineered its one-step C-LiNK enzymatic method of peptide-based, site-specific conjugation for making antibody-drug conjugates. According to Eucodis, the technology covalently links toxins or other molecules to the C-terminus of either antibody chain, without disturbing the native antibody structure and at a defined antibody-drug ratio.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter